IN2014DN06965A - - Google Patents

Info

Publication number
IN2014DN06965A
IN2014DN06965A IN6965DEN2014A IN2014DN06965A IN 2014DN06965 A IN2014DN06965 A IN 2014DN06965A IN 6965DEN2014 A IN6965DEN2014 A IN 6965DEN2014A IN 2014DN06965 A IN2014DN06965 A IN 2014DN06965A
Authority
IN
India
Prior art keywords
relates
pregabalin
preparation
pharmaceutically acceptable
acrylic acid
Prior art date
Application number
Inventor
Varinder Kumar
Shavej Ahmad
Romi Barat Singh
Original Assignee
Ranbaxy Lab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Lab Ltd filed Critical Ranbaxy Lab Ltd
Priority to IN6965DEN2014 priority Critical patent/IN2014DN06965A/en
Publication of IN2014DN06965A publication Critical patent/IN2014DN06965A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

The present invention relates to a gastroretentive tablet comprising pregabalin, an acrylic acid polymer, one or more swellable polymers, and other pharmaceutically acceptable excipients. It further relates to a process for the preparation of same.
IN6965DEN2014 2012-01-30 2013-01-29 IN2014DN06965A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
IN6965DEN2014 IN2014DN06965A (en) 2012-01-30 2013-01-29

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN249DE2012 2012-01-30
IN6965DEN2014 IN2014DN06965A (en) 2012-01-30 2013-01-29
PCT/IB2013/050762 WO2013114281A1 (en) 2012-01-30 2013-01-29 Pregabalin gr tablets

Publications (1)

Publication Number Publication Date
IN2014DN06965A true IN2014DN06965A (en) 2015-04-10

Family

ID=48014112

Family Applications (1)

Application Number Title Priority Date Filing Date
IN6965DEN2014 IN2014DN06965A (en) 2012-01-30 2013-01-29

Country Status (6)

Country Link
US (1) US20140378545A1 (en)
EP (1) EP2809303A1 (en)
AU (1) AU2013213859A1 (en)
CA (1) CA2863371A1 (en)
IN (1) IN2014DN06965A (en)
WO (1) WO2013114281A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102221846B1 (en) * 2014-04-07 2021-02-26 영진약품 주식회사 Pharmaceutical composition of pregabalin with improved stability and method for preparing thereof
CN108159011A (en) * 2018-03-16 2018-06-15 中国药科大学 A kind of Pregabalin stomach retention sustained-release piece of biphasic controlled release and preparation method thereof
EP3760190B1 (en) * 2019-07-03 2023-05-24 Alvogen, Inc. Controlled-release tablets of pregabalin, method of making, and method of use thereof
TWI733299B (en) * 2020-01-07 2021-07-11 華宇藥品股份有限公司 Sustained-release formulation of pregabalin
CN113577036B (en) * 2021-05-31 2023-04-04 石药集团欧意药业有限公司 Pregabalin gastric floating sustained release tablet and preparation method thereof
CN115721600B (en) * 2022-11-10 2025-08-22 济川(上海)医学科技有限公司 A gastric retentive pregabalin sustained-release composition and preparation method thereof
CN120324357A (en) * 2025-06-03 2025-07-18 上海国创医药股份有限公司 A pregabalin sustained-release composition and preparation method thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6197819B1 (en) 1990-11-27 2001-03-06 Northwestern University Gamma amino butyric acid analogs and optical isomers
US5869029A (en) * 1996-06-21 1999-02-09 Hercules Incorporated Dispersible water-soluble or water-swellable polymers and process for making toothpastes containing them
SI0934061T1 (en) 1996-07-24 2003-10-31 Warner-Lambert Company Llc Isobutylgaba and its derivatives for the treatment of pain
NL2000281C2 (en) 2005-11-02 2007-08-07 Pfizer Prod Inc Solid pharmaceutical compositions containing pregabalin.
WO2009066325A1 (en) 2007-11-23 2009-05-28 Lupin Limited Controlled release pharmaceutical compositions of pregabalin
WO2010143052A1 (en) 2009-06-12 2010-12-16 Micro Labs Limited Novel pharmaceutical compositions containing pregabalin
EP2389933A1 (en) * 2010-05-25 2011-11-30 Sanovel Ilac Sanayi ve Ticaret A.S. Controlled-Release Pregabalin Compositions
IN2012MN02923A (en) 2010-06-01 2015-06-05 Rubicon Res Private Ltd
WO2013114283A1 (en) * 2012-01-30 2013-08-08 Ranbaxy Laboratories Limited Gastroretentive tablets

Also Published As

Publication number Publication date
AU2013213859A1 (en) 2014-08-21
WO2013114281A1 (en) 2013-08-08
EP2809303A1 (en) 2014-12-10
CA2863371A1 (en) 2013-08-08
US20140378545A1 (en) 2014-12-25

Similar Documents

Publication Publication Date Title
IN2014DN06966A (en)
IN2014DN06965A (en)
PH12015500561A1 (en) Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same
MX2014004862A (en) Acrylic polymer formulations.
MX364229B (en) COMPOSITIONS and METHODS FOR TREATING CARDIOVASCULAR DISEASES.
PH12018501072A1 (en) Modified release orally administered amino acid formulations
EP3102188A4 (en) Novel disintegration systems for pharmaceutical dosage forms
PH12013500981A1 (en) Process for the preparation of a ppi-containing pharmaceutical product
EA201692043A1 (en) DOSAGE FORM IMMUNODEPRESSANT
EP3102585A4 (en) Boronic acid esters and pharmaceutical formulations thereof
MX2016005477A (en) Abuse-deterrent dosage forms.
PH12014502856A1 (en) Solid pharmaceutical preparation containing levothyroxine
MX2016006087A (en) Rapidly disintegrating formulations and methods of use.
PH12014501840A1 (en) Pharmaceutical formulation having improved stability
HK1244692A1 (en) Methods of treating fibrosis
IN2014DN07191A (en)
PH12014502325B1 (en) Sustained release tablet containing levodropropizine and method for preparing same
EA201791089A1 (en) PHARMACEUTICAL MATRIXES CONTAINING CONTAINING DIMETHYLFUMARATE
MX2015008171A (en) Formulation comprising amorphous agomelatine.
ES1093280Y (en) Connector set for medical gas applications
WO2016137266A3 (en) Pharmaceutical composition containing eperisone and pelubiprofen
WO2014013090A3 (en) Formulation comprising amorphous fingolimod
IN2014MU00215A (en)
WO2013115736A3 (en) Bilayer tablet formulations of flurbiprofen and glucosamin
IN2013MU02631A (en)